Thieler Law Corp, member of the Investor Attorney Network, is investigating whether certain officers and directors of Geron Corporation (NASDAQ: GERN) violated securities laws in connection with certain financial statements.

The investigation seeks to discover if possible claims on behalf of purchasers of the securities of Geron Corporation (NASDAQ: GERN) concerning whether a series of statements by Geron Corporation regarding its business, its prospects and its operations were materially false and misleading at the time they were made.

On March 27, 2017, a report published by STAT, written by Adam Feuerstein, stated that the Geron 's recent stock performance was due to "flimsy" claims with respect to the efficacy of imetelstat, Geron's experimental myelofibrosis treatment. Adam Feuerstein stated that the available data for imetelstat undercuts Geron's representations as to the drug's efficacy.

Following this news, NASDAQ: GERN fell $0.83 or over 13% to close at $5.15 per share on March 27, 2018. Geron shares continue to fall sharply during intraday trading on March 28, 2018.

Based in Menlo Park, California, and founded in 1990 Geron Corporation operates as a biopharmaceutical company

If you purchased shares of Geron Corporation (NASDAQ: GERN) on or before March 27, 2017, you should contact Thieler Law Corp at mail@thielerlaw.com or call +1 (619) 377 - 4324.

Thieler Law Corp

2534 State Street - Suite 406,

San Diego, CA 92101

by

email: mail@thielerlaw.com 

or

telephone at +1 (619) 377 - 4324

or

visit our website http://www.thielerlaw.com/ 

or

Facsimile: +1 (619) 785 – 3185